Former Portfolio Companies

Bolt is a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer.

IPO in 2021 (TK: BOLT) Redwood City, CA visit www.boltbio.com